Prenylation is not necessary for endogenous Ras activation in non-malignant cells

Journal of Cellular Biochemistry

Volumn 97, Issue 2, 2006, Pages 412-422

  Khwaja, Arif ^a,b   Dockrell, Mark E C ^a,c   Hendry, Bruce M ^a   Sharpe, Claire C ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c ST HELIER HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cell proliferation; Endogenous; Prenylation; Ras isoforms; Ras monomeric GTPases

Indexed keywords

EPIDERMAL GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; RAF PROTEIN; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; CELL TRANSFORMATION; CELL TYPE; CONTROLLED STUDY; FIBROBLAST; GENE ACTIVATION; GENE ACTIVITY; HUMAN; HUMAN CELL; KIDNEY CELL; MEMBRANE BINDING; MESANGIUM CELL; NONHUMAN; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; VERO CELL; WILD TYPE;

ANIMALS; CELL FRACTIONATION; CELL MEMBRANE; CELL PROLIFERATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CYTOSOL; GUANOSINE TRIPHOSPHATE; HUMANS; KIDNEY CORTEX; MESANGIAL CELLS; PROTEIN ISOPRENYLATION; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; VERO CELLS;

ANIMALIA; PRIMATES;

EID: 31544464050     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20641     Document Type: Article

References (35)

1. Apolloni A, Prior IA, Lindsay M, Parton RG, Hancock JF. 2000. H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol Cell Biol 20:2475-2487.
2. Barbacid M. 1987. ras genes. Annu Rev Biochem 56:779-827.
3. Bivona TG, Perez De Castro I, Ahearn IM, Grana TM, Chiu VK, Lockyer PJ, Cullen PJ, Pellicer A, Cox AD, Philips MR. 2003. Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature 424:694-698.
4. Bos JL. 1988. The ras gene family and human carcinogenesis. Mutat Res 195:255-271.
5. Chen G, Oh S, Monia BP, Stacey DW. 1996. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 271:28259-28265.
6. Cory AH, Owen TC, Barltrop JA, Cory JG. 1991. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3:207-212.
7. Cox AD, Solski PA, Jordan JD, Der CJ. 1995. Analysis of Ras protein expression in mammalian cells. Methods Enzymol 255:195-220.
8. Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
9. Fiordalisi JJ, Johnson RL, 2nd, Weinbaum CA, Sakabe K, Chen Z, Casey PJ, Cox AD. 2003. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. J Biol Chem 278:41718-41727.
10. Gibbs JB, Oliff A, Kohl NE. 1994. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175-178.
11. Hill BT, Perrin D, Kruczynski A. 2000. Inhibition of RAS-targeted prenylation: Protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol 33:7-23.
12. Hirai A, Nakamura S, Noguchi Y, Yasuda T, Kitagawa M, Tatsuno I, Oeda T, Tahara K, Terano T, Narumiya S, Kohn LD, Saito Y. 1997. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272: 13-16.
13. Inouye K, Mizutani S, Koide H, Kaziro Y. 2000. Formation of the Ras dimer is essential for Raf-1 activation. J Biol Chem 275:3737-3740.
14. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC, Jr. 1993. Benzodiazepine peptidomimetics: Potent inhibitors of Ras farnesylation in animal cells. Science 260:1937-1942.
15. James GL, Goldstein JL, Brown MS. 1995. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270:6221-6226.
16. Lerner EC, Qian Y, Hamilton AD, Sebti SM. 1995. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270:26770-26773.
17. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. 1997. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15:1283-1288.
18. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM. 1995. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55:5310-5314.
19. Osman H, Mazet JL, Maume G, Maume BF. 1997. Geranylgeranyl as well as farnesyl moiety is transferred to Ras p21 overproduced in adrenocortical cells transformed by c-Ha-rasEJ oncogene. Biochem Biophys Res Commun 231:789-792.
20. Prendergast GC. 2000. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 12:166-173.
21. Prior IA, Hancock JF. 2001. Compartmentalization of Ras proteins. J Cell Sci 114:1603-1608.
22. Prior IA, Harding A, Yan J, Sluimer J, Parton RG, Hancock JF. 2001. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat Cell Biol 3:368-375.
23. Rocks O, Peyker A, Kahms M, Verveer PJ, Koerner C, Lumbierres M, Kuhlmann J, Waldmann H, Wittinghofer A, Bastiaens PI. 2005. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 307:1746-1752.
24. Roy S, McPherson RA, Apolloni A, Yan J, Lane A, Clyde-Smith J, Hancock JF. 1998. 14-3-3 facilitates Ras- dependent Raf-1 activation in vitro and in vivo. Mol Cell Biol 18:3947-3955.
25. Scharovsky OG, Rozados VR, Gervasoni SI, Matar P. 2000. Inhibition of ras oncogene: A novel approach to antineoplastic therapy. J Biomed Sci 7:292-298.
26. Sebti SM, Adjei AA. 2004. Farnesyltransferase inhibitors. Semin Oncol 31:28-39.
27. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N. 1995. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res 55:5302-5309.
28. Sharpe CC, Dockrell ME, Scott R, Noor MI, Cowsert LM, Monia BP, Hendry BM. 1999. Evidence of a role for Ki-Ras in the stimulated proliferation of renal fibroblasts. J Am Soc Nephrol 10:1186-1192.
29. Sharpe CC, Dockrell ME, Noor MI, Monia BP, Hendry BM. 2000. Role of Ras isoforms in the stimulated proliferation of human renal fibroblasts in primary culture. J Am Soc Nephrol 11:1600-1606.
30. Sinensky M. 2000. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 1484:93-106.
31. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP. 1996. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 271:9690-9697.
32. Sun J, Qian Y, Hamilton AD, Sebti SM. 1998. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16:1467-1473.
33. Suzuki N, Urano J, Tamanoi F. 1998. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA 95:15356-15361.
34. Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. 1996. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13:1991-1999.
35. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. 1997. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 272:27224-27229.